| Hannah Roche, PHARMD | |
|
700 E Avalon St, Kuna, ID 83634-2140 | |
| (208) 922-9836 | |
| Not Available |
| Full Name | Hannah Roche |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 700 E Avalon St, Kuna, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760155915 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | P9490 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Hannah Roche, PHARMD 521 Blue Sky Dr, Kuna, ID 83634-2117 Ph: (208) 813-8804 | Hannah Roche, PHARMD 700 E Avalon St, Kuna, ID 83634-2140 Ph: (208) 922-9836 |
News Archive
Even on a good day, DNA is constantly getting damaged. Nicks, scratches, breaks: the delicate strands that carry life's genetic code take a beating as they jumble about in the course of their work. If left untreated, errors accumulate, with fatal consequences - such as cancerous tumors - for the cell and the organism.
A study released today "online first" in Cancer Causes & Control demonstrates that human papillomavirus testing, using QIAGEN's digene HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk types of HPV that can cause cervical cancer.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
Researchers at University of California San Diego School of Medicine, Texas A&M College of Medicine and the Omni-Net Birth Defects Prevention Program in Ukraine have identified a blood test that may help predict how severely a baby will be affected by alcohol exposure during pregnancy, according to a study published November 9 in the journal PLOS ONE.
› Verified 2 days ago
Travis Walthall, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 173 W 4th St, Kuna, ID 83634 Phone: 208-922-4400 Fax: 208-922-4499 | |
William Thompson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 E Avalon St, Kuna, ID 83634 Phone: 208-922-9836 | |
Chandler Rieske, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 E Avalon St, Kuna, ID 83634 Phone: 208-922-9836 | |
Shawn Barrow, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 869 E Avalon St, Kuna, ID 83634 Phone: 208-319-0205 | |
Katie Yvonne Gonzalez, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 869 E Avalon St, Kuna, ID 83634 Phone: 208-319-0205 Fax: 208-319-0211 | |
Denni Tiegs, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 E Avalon St, Kuna, ID 83634 Phone: 208-922-9834 | |
Dr. Eric Brandon Schlerf, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 173 W 4th St, Kuna, ID 83634 Phone: 208-922-4400 Fax: 208-922-4499 |